Opus Genetics (IRD) Share-based Compensation (2010 - 2026)
Opus Genetics (IRD) posted quarterly Share-based Compensation of $1.5 million for Q1 2026, up 60.35% year-over-year from $913000.0 in Q1 2025, and down 55.62% quarter-over-quarter from $3.3 million in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Share-based Compensation (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Share-based Compensation for 17 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 60.35% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $8.8 million (up 81.07% YoY), while the FY2025 annual figure was $5.7 million, down 6.56% from the prior year.
- Share-based Compensation eased to $1.5 million in Q1 2026 per IRD's latest filing, from $3.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.1 million in Q2 2025 and bottomed at $445000.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $913000.0 in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 1796.15% — and 2024, when it slumped 43.32%.
- Opus Genetics' Share-based Compensation stood at $493000.0 in 2022, then jumped by 44.22% to $711000.0 in 2023, then jumped by 344.73% to $3.2 million in 2024, then gained by 4.33% to $3.3 million in 2025, then slumped by 55.62% to $1.5 million in 2026.
- Business Quant data shows IRD's Share-based Compensation at $1.5 million in Q1 2026, $3.3 million in Q4 2025, and $6.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | 1.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Mn |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | 774,000.00 |
| Sep 30, 2025 | 29.43 Mn |
| Jun 30, 2025 | 29.43 Mn |
| Mar 31, 2025 | 29.43 Mn |
| Dec 31, 2024 | 795,000.00 |
| Sep 30, 2024 | 4.85 Mn |
| Jun 30, 2024 | 4.96 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Dec 31, 2023 | 711,000.00 |
| Sep 30, 2023 | 3.47 Mn |
| Jun 30, 2023 | 3.44 Mn |
| Mar 31, 2023 | 247.00 Mn |
| Dec 31, 2022 | 424,000.00 |
| Sep 30, 2022 | 493,000.00 |
| Jun 30, 2022 | 445,000.00 |
| Mar 31, 2022 | 2.62 Mn |
| Dec 31, 2021 | 479,000.00 |
| Sep 30, 2021 | 478,000.00 |